2L
ITOS

25 LLC’s iTeos Therapeutics ITOS Stock Holding History

25 LLC’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-34
Closed -$473 – 269
2023
Q2 		$473 Buy
+34
New +$485 ﹤0.01% 575

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

25 LLC's ITOS Position: Q3 2023 in Review

25 LLC sold out of iTeos Therapeutics (ITOS) in Q3 2023, closing a stake of 34 shares — an estimated $473 sold.

25 LLC first reported a position in ITOS in Q2 2023 and held it in 1 quarter. The position peaked at $473 in Q2 2023. 144 funds tracked by Wall St. Rank hold ITOS as of Q3 2023.

  • 25 LLC reported no remaining iTeos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • 25 LLC sold 34 iTeos Therapeutics shares in Q3 2023, an estimated $473.
  • 25 LLC first reported a position in iTeos Therapeutics in Q2 2023 and held it in 1 quarter.
  • 25 LLC's iTeos Therapeutics position peaked at $473 in Q2 2023.
  • 144 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.